Sanofi: Renal Insufficiency trials
The registry lists 12 Renal Insufficiency studies with Sanofi as lead sponsor. 1 are open to participants now and 3 have results posted.
Phase 1 6Phase 2 2Phase 3 2Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal FunctionRecruitingNCT07853131Phase 1
- Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal ImpairmentTerminatedNCT05552859Phase 4Results posted
- Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsCompletedNCT00985426Phase 3Results posted
- Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal ImpairmentCompletedNCT00445302Phase 1Results posted
- Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.CompletedNCT05282030Phase 1
- Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal DialysisCompletedNCT01724788Phase 1
- Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal ImpairmentCompletedNCT01239459Phase 1
- Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on HemodialysisCompletedNCT01195246Phase 3
- Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal ImpairmentCompletedNCT01120314Phase 1
- A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal DiseaseTerminatedNCT00498212Phase 2
- Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary HyperparathyroidismCompletedNCT00123461Phase 4
- Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant RejectionCompletedNCT00117689Phase 2